Clinical study on Cangma Huadu Granules treating mild COVID-19

ABSTRACT

ConditionCOVID-19

InterventionExperimental groupBasic treatment + Cangma Huadu granules;Control groupBasic treatment + placebos;

Primary outcome:Clinical symptom remission time;

CriteriaInclusion criteria (1) Patients who have been diagnosed with mild COVID-19 according to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial Version 9);
(2) 60 years old =aged =18 years old;
(3) Treatment time from onset to inclusion =72h;
(4) The patient is informed and agrees to sign the informed consent.

Exclusion criteria (1) Mentally ill persons, or other persons unable to cooperate or unwilling to cooperate;
(2) Participants in other trials within the last 3 months;
(3) The patient is known to have the following risk factors
a) Pregnant women or women in the puerperal period;
b) Chronic respiratory diseases, including COPD and asthma attacks;
c) neurological diseases and neurodevelopmental disorders, including brain, spinal cord, peripheral nerve and muscle diseases (e.g., cerebral palsy, epilepsy [convulsive attacks], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy or spinal cord injury);
d) Heart disease (e.g., congenital heart disease, congestive heart failure or coronary artery disease), excluding high blood pressure without any other heart-related symptoms;
e) Diseases of the blood system;
f) endocrine system diseases (excluding HBA1c < 8%);
g) Kidney disease creatinine clearance =60 mL/min;
h) Liver diseases (including hepatitis, cirrhosis, moderate to severe fatty liver, but excluding asymptomatic abnormal liver function with AST or ALT elevated less than 50% of the upper limit of normal);
i) Metabolic disorders (protein metabolism, glucose metabolism, lipid metabolism, water and electrolyte metabolism, hyperuricemia);
j) compromised immune systems (including patients on immunosuppressive therapy, or patients with cancer or human immunodeficiency virus [HIV] infection);
k) Obese patients (body mass index [BMI]=30).
(4) Weight of indicator cases < 40 kg;
(5) a history of alcohol or drug abuse;
(6) have received or are receiving anti-COVID-19 drugs such as Ritonavir and azfudine tablets;
(7) Antipyretic and analgesic drugs were used within 6 hours;
(8) Chinese patent medicines with antiviral properties (such as Jinhua Qinggan, Lianhua Qingwen, Qingkailing Granules (oral liquid), Shufeng Jiedu capsules, Yinqiao Jiedu, Sangju colds, Yinhuang preparations) should be used within 12h